EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease

Emidio Scarpellini iD, Marialaura Scarcella, Jan F Tack, Giuseppe Guido Maria Scarlata iD, Michela Zanetti, Ludovico Abenavoli iD

Antioxidants · 14.11.2024 · 13 (11) · 1386

DOI: 10.3390/antiox13111386 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 14.11.2024. Verfasst von Emidio Scarpellini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research in Gastroeintestinal Disorders, Gasthuisberg University Hospital, KULeuven, Herestraat 49, 3000 Lueven, Belgium. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The gut microbiota constitutes a complex microorganism community that harbors bacteria, viruses, fungi, protozoa, and archaea. The human gut bacterial microbiota has been extensively proven to participate in human metabolism, immunity, and nutrient absorption. Its imbalance, namely “dysbiosis”, has been linked to disordered metabolism. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the features of deranged human metabolism and is the leading cause of liver cirrhosis and hepatocellular carcinoma. Thus, there is a pathophysiological link between gut dysbiosis and MASLD. Aims and Methods: We aimed to review the literature data on the composition of the human bacterial gut microbiota and its dysbiosis in MASLD and describe the concept of the “gut–liver axis”. Moreover, we reviewed the approaches for gut microbiota modulation in MASLD treatment.

Results

There is consolidated evidence of particular gut dysbiosis associated with MASLD and its stages. The model explaining the relationship between gut microbiota and the liver has a bidirectional organization, explaining the physiopathology of MASLD. Oxidative stress is one of the keystones in the pathophysiology of MASLD and fibrosis generation. There is promising and consolidated evidence for the efficacy of pre- and probiotics in reversing gut dysbiosis in MASLD patients, with therapeutic effects. Few yet encouraging data on fecal microbiota transplantation (FMT) in MASLD are available in the literature.

Conclusions

The gut dysbiosis characteristic of MASLD is a key target in its reversal and treatment via diet, pre/probiotics, and FMT treatment. Oxidative stress modulation remains a promising target for MASLD treatment, prevention, and reversal.

Schlagwörter

Stichwörter der Autor:innen

dysbiosisgut microbiotagut–liver axisliver steatosisoxidative stressprobiotics

Autor:innen und Institutionen

  • Translational Research in Gastroeintestinal Disorders, Gasthuisberg University Hospital, KULeuven, Herestraat 49, 3000 Lueven, Belgium.
  • Anesthesia, Intensive Care and Nutritional Science-Azienda Ospedaliera "Santa Maria", Via Tristano di Joannuccio, 05100 Terni, Italy.
  • Department of Health Sciences, University "Magna Graecia", 88100 Catanzaro, Italy.
  • Geriatrics Department, Nutrition and Malnutrition Unit, Azienda Sanitario-Universitaria Giuliano Isontina, Ospedale Maggiore, piazza dell'Ospitale 1, 34100 Triste, Italy.

ORCID-Profile: Emidio Scarpellini, Giuseppe Guido Maria Scarlata, Ludovico Abenavoli

Zitieren

APA

Scarpellini, E., Scarcella, M., Tack, J. F., Scarlata, G. G. M., Zanetti, M., & Abenavoli, L. (2024). Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease. Antioxidants, 13(11), 1386. https://doi.org/10.3390/antiox13111386

Vancouver

Scarpellini E, Scarcella M, Tack JF, Scarlata GGM, Zanetti M, Abenavoli L. Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease. Antioxidants. 2024;13(11):1386. doi:10.3390/antiox13111386

BibTeX
@article{Scarpellini2024,
  author = {Scarpellini, Emidio and Scarcella, Marialaura and Tack, Jan F and Scarlata, Giuseppe Guido Maria and Zanetti, Michela and Abenavoli, Ludovico},
  title = {Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease},
  journal = {Antioxidants},
  year = {2024},
  volume = {13},
  number = {11},
  pages = {1386},
  doi = {10.3390/antiox13111386}
}
Kostenlos starten →